Heart Rhythm Concerns Prompt EU-Wide Suspension For Fenspiride Cough Medicines
Executive Summary
Fenspiride medicines are being suspended while the European Medicines Agency's pharmacovigilance committee carries out an urgent safety review to address concerns that these drugs can cause sudden serious heart rhythm problems.
You may also be interested in...
Blood Clot Concerns Prompt EU Restrictions For Pfizer's Xeljanz
The European Medicines Agency's pharmacovigilance committee has launched a fresh review of Xeljanz and has also recommended suspending all fenspiride medicines, which are used to treat non-serious cough but are associated with heart rhythm problems.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.